ABCL:NSD-AbCellera Biologics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 15.28

Change

-0.25 (-1.61)%

Market Cap

USD 4.33B

Volume

1.07M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.

Company Website : http://www.abcellera.com

Address : 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1

Employees : 302

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 71.91

Short Ratio : 2.48

52 Week Low : 14.51

Shorted Shares : 8,115,880

200 Day Moving Average : 22.05

Shorted Shares Previous Month : 7,857,905

50 Day Moving Average : 18.10

Shares Held By Insiders : 31.51%

Short Percentage : 3.00%

Shares Held by Institutions : 47.91%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+10.63 (+3.28%)

 USD130.87B 38.30 29.43
BNTX BioNTech SE

+13.41 (+5.41%)

 USD60.07B 13.82 10.18
REGN Regeneron Pharmaceuticals Inc

-9.76 (-1.76%)

 USD59.17B 9.99 7.57
VRTX Vertex Pharmaceuticals Incorpo..

-0.97 (-0.53%)

 USD47.16B 23.96 15.75
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+2.38 (+0.66%)

 USD33.45B N/A N/A
SGEN Seagen Inc

-0.76 (-0.44%)

 USD31.43B 53.89 40.74
GMAB Genmab A/S

+0.07 (+0.16%)

 USD29.05B 74.96 8.12
ALNY Alnylam Pharmaceuticals Inc

-4.66 (-2.23%)

 USD24.79B N/A N/A
RPRX Royalty Pharma plc

-1.37 (-3.57%)

 USD23.31B 31.09 11.82

ETFs Containing ABCL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -62.03% 8% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.03% 8% F 5% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 4.33B 92% A- 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 20.99 31% F 43% F
Price/Book Ratio 4.28 42% F 33% F
Price / Cash Flow Ratio 190.76 1% F 3% F
EV/EBITDA 10.27 32% F 64% D
Management Effectiveness  
Return on Equity 43.31% 98% A+ 96% A
Return on Invested Capital 29.62% 92% A- 94% A
Return on Assets 29.83% 99% A+ 99% A+
Debt to Equity Ratio 0.26% 83% B 90% A-
Technical Ratios  
Short Ratio 2.48 67% D+ 57% F
Short Percent 4.58% 54% F 37% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.